Solid Biosciences Announces Board of Directors Reclassification and Reappointment of Ilan Ganot

On April 10, 2026, Solid Biosciences Inc. announced a formal restructuring of its Board of Directors to achieve an equal balance of membership across its three classes. Ilan Ganot resigned from his position as a Class III director (term originally expiring in 2027) and was immediately reappointed as a Class I director. His new term will expire at the Company’s 2028 Annual Meeting of Stockholders. Simultaneously with this change, the Board adjusted the number of seats in each class, decreasing Class III to three directors and increasing Class I to three directors. The company noted that this maneuver was intended solely for governance balancing purposes. There were no changes to Mr. Ganot’s compensation arrangements, and no compensation is due as a result of the resignation and reappointment. To align with corporate governance best practices, the company will ask stockholders to ratify Mr. Ganot’s appointment as a Class I director on an advisory basis at the 2026 Annual Meeting of Stockholders.